摘要
克罗恩病是一种以累及消化道为主的复发性炎性疾病。生物制剂的使用为克罗恩病的治疗提供了新的方向。大量临床研究已证实生物治疗主要是抗TNFα单抗对诱导及维持克罗恩病临床缓解、预防并发症的发生有效。目前临床指南多建议对克罗恩病采取递增方案治疗,对重度患者可及早采取更为有效的包括生物治疗在内的治疗方式,但递减治疗方案在临床中的应用尤其是针对初次诊断者也越来越受到重视。目前早期及长期应用生物治疗的安全性及其是否能改变克罗恩病的自然病程证据尚不充分。应针对患者的不同情况,根据风险/效益研究来确定更合适的治疗方案。
Crohn＇s disease （CD） is a relapsing systemic inflammatory disease mainly affecting the gastrointestinal tract. The introduction of biologic therapies has offered new therapeutic opportunities. The efficacy of anti-TNF αtherapy of inducing and maintaining clinical remission and prevent the risk of complications of CD has been evaluated in numerous clinical trials. Current guidelines recommend a step-up strategy consisting of a progressive treatment including biologics in severe disease. An early introduction of biologics in newly diagnosed CD has been advocated （top-down strategy）. No strong evidence supports the safety and efficacy of early and long-term treatment in modifying the natural history of CD. The ultimate application of use of biologics will likely be established by risk/benefit studies according to certain individuals.
出处
《医学与哲学（B）》
2013年第4期10-12,23,共4页
Medicine & Philosophy(B)
基金
国家自然科学基金"MiR-193a-3p调控结肠上皮PepT1表达在溃疡性结肠炎发病机制中的作用研究"
项目编号:81200281
关键词
克罗恩病
生物制剂
生物治疗
Crohn＇ s disease, biologics, biologic therapies
